Details for New Drug Application (NDA): 201367
✉ Email this page to a colleague
The generic ingredient in BANZEL is rufinamide. There are seven drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the rufinamide profile page.
Summary for 201367
Tradename: | BANZEL |
Applicant: | Eisai Inc |
Ingredient: | rufinamide |
Patents: | 0 |
Suppliers and Packaging for NDA: 201367
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
BANZEL | rufinamide | SUSPENSION;ORAL | 201367 | NDA | Eisai Inc. | 62856-584 | 62856-584-46 | 1 BOTTLE in 1 CARTON (62856-584-46) / 460 mL in 1 BOTTLE |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | SUSPENSION;ORAL | Strength | 40MG/ML | ||||
Approval Date: | Mar 3, 2011 | TE: | AB | RLD: | Yes |
Expired US Patents for NDA 201367
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Eisai Inc | BANZEL | rufinamide | SUSPENSION;ORAL | 201367-001 | Mar 3, 2011 | 6,740,669*PED | ⤷ Subscribe |
Eisai Inc | BANZEL | rufinamide | SUSPENSION;ORAL | 201367-001 | Mar 3, 2011 | 7,750,028*PED | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription